Thrombosis and Thromboembolism

1. What’s New with TG and AngPTL3 – Aruna D. Pradhan, MD, MPH, MSc

2. What’s New with Lp(a) – Samia Mora, MD

3. What’s New with LDL and ApoB – Jorge Plutzky, MD

4. What’s New with Inflammatory Targets – Paul M. Ridker, MD, MPH

5. Discussion/Q&A – John F. Keaney, Jr., MD

1. PAD – Pathways for Optimizing Cardiovascular and Limb Outcomes – Marc P. Bonaca, MD, MPH

2. Discussion/Q&A – Marie D. Gerhard-Herman, MD

1. Heart Failure and Venous Thromboembolism – Samuel Z. Goldhaber, MD

2. More Than Just Diabetes and Heart Failure – SGLT2 – Deepak L. Bhatt, MD, MPH

3. More Than Just Diabetes and Heart Failure – GLP1 – Brendan M. Everett, MD, MPH

4. Heart Failure – Reduced Ejection Fraction – Marc A. Pfeffer, MD, PhD

5. Discussion/Q&A – Akshay Suvas Desai, MD, MPH

6. Heart Failure – Preserved Ejection Fraction – Scott D. Solomon, PhD

7. Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup – Michele A. Hamilton, MD

8. Imaging of Heart Failure – Raymond Y. Kwong, MD, MPH

1. Dual Antiplatelet Therapy and Anticoagulation – Michelle L. O’Donoghue, MD, MPH

2. How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF – Bruce A. Koplan, MD

1. Dose-Reduced Direct Oral Anticoagulants – Efficacy and Safety – Behnood Bikdeli, MD, MS

2. Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data and Variations in Practice – Teresa Carman, MD, RPVI, MSV

3. Duration of Anticoagulation – Venous Thrombosis – Gregory Piazza, MD, MS

4. Novel Anticoagulation Targets – Factor XI and XII Inhibitors – Jeffrey I. Weitz, MD

5. Discussion/Q&A – Samuel Z. Goldhaber, MD

1. Racial Disparities in Healthcare – Cassandra M. Pierre, MD, MSc, MPH

2. Racial Disparities in Arterial and Venous Thrombosis – Karlyn A. Martin, MD, MS

3. Discussion/Q&A – Gregory Piazza, MD, MS

1. VTE Prediction – Using Genetics as a Powerful Tool – Nicholas A. Marston, MD, MPH

2. Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD – Peter Libby, MD

3. Discussion/Q&A – Gregory Piazza, MD, MS

1. COVID and Thrombosis – Mechanisms and Epidemiology – Gregory Piazza, MD, MS

2. Prevention of VTE in COVID-19 Patients – Behnood Bikdeli, MD, MS

3. Discussion/Q&A – Samuel Z. Goldhaber, MD

1. VTE Prophylaxis for Orthopedic Surgery – Samuel Z. Goldhaber, MD

2. Discussion/Q&A – Ebrahim Barkoudah, MD, MPH

1. Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape – Gregory Piazza, MD, MS

2. Systemic Fibrinolysis (PEITHO-3) – Samuel Z. Goldhaber, MD

1. Adventures with Hypertrophic Cardiomyopathy – 1958-2022 – Eugene Braunwald, MD

1. Chronic Thromboembolic Pulmonary Hypertension – Bradley A. Maron, MD

2. Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension – Jane A. Leopold, MD

1. Post-thrombotic Syndrome – Epidemiology and Medical Therapy – Susan R. Kahn, MD, MSc, FRCPC, ABIM

2. Intervention, Acute Intervention, and Chronic Venous Obstructive Disease – Suresh Vedantham, MD

3. Discussion/Q&A – Arvind K. Pandey, MD

1. Vascular Cardio-Oncology – Javid Moslehi, MD

2. Prevention of Thrombotic Complications of Cancer and Cancer Therapy – Simon Mantha, MD, MPH

3. Treatment of Cancer-Associated Thrombosis – Michael B. Streiff, MD

4. Discussion/Q&A – Jean Connors, MD